In fact, by combining the results of Omics data and available clinical/biological parameters, the International Neuroblastoma Risk Group (INRG) task force has established a stratification system of neuroblastoma patients taking into consideration diverse prognostic factors (i.e., clinical stage, patient’s age at diagnosis, tumour histology (Shimada system) [4], grade of tumour differentiation, MYCN oncogene amplification, 11q deletion and DNA ploidy). Here, MYCN is linked to neuroblastoma.